A Study of EBC-129 in Advanced Solid Tumours

NCT ID: NCT05701527

Last Updated: 2026-02-05

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 98 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-28
• Study Completion Date: 2026-12-24

Brief Summary

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

Detailed Description

This study is a prospective, open label study which is divided into 4 parts.

Part A will be dose escalation segment to identify the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of EBC-129 monotherapy.

Part B will be dose escalation segment to identify the MTD and RP2D of EBC-129 in combination with pembrolizumab.

Part C (dose expansion cohort) will be performed in an expanded cohort of patients with advanced solid malignancies at the RP2D of EBC-129 as a monotherapy identified in the dose escalation segment, Part A.

Part D (Dose Fractionation Cohort) will be performed in patients with advanced solid malignancies with cancer indications that have shown preliminary clinical activity in Part C.

Conditions

Advanced Solid Tumours

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part A-Cohort 1

Patients will be administered Dose 1 of EBC-129 as a monotherapy.

Group Type: EXPERIMENTAL

EBC-129

Intervention Type: DRUG

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

Part A-Cohort 2

Patients will be administered Dose 2 of EBC-129 as a monotherapy.

Group Type: EXPERIMENTAL

EBC-129

Intervention Type: DRUG

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

Part A-Cohort 3

Patients will be administered Dose 3 of EBC-129 as a monotherapy.

Group Type: EXPERIMENTAL

EBC-129

Intervention Type: DRUG

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

Part A-Cohort 4

Patients will be administered Dose 4 of EBC-129 as a monotherapy.

Group Type: EXPERIMENTAL

EBC-129

Intervention Type: DRUG

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

Part A-Cohort 5

Patients will be administered Dose 5 of EBC-129 as a monotherapy.

Group Type: EXPERIMENTAL

EBC-129

Intervention Type: DRUG

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

Part B

Patients will be administered three different dose levels of EBC-129 in combination with a fixed dose of pembrolizumab.

Group Type: EXPERIMENTAL

EBC-129

Intervention Type: DRUG

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.

Part C

Patients will be administered the highest dose of EBC-129 as a monotherapy at the RP2D determined in Part A of the study.

Group Type: EXPERIMENTAL

EBC-129

Intervention Type: DRUG

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

Part D: EBC-129

Patients will be administered EBC-129 as a monotherapy as per two-dose or three-dose per cycle regimen.

Group Type: EXPERIMENTAL

EBC-129

Intervention Type: DRUG

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

Interventions

EBC-129

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

Intervention Type: DRUG

Pembrolizumab

Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female patients ≥18 years (US) or ≥21 years (Singapore) old

2. Body weight within ≥40 kg - ≤100 kg during Parts A and B, and ≤120 kg during all other parts of the study

3. Demonstrated progression of a locally advanced unresectable or metastatic solid tumour with no alternative standard-of-care therapeutic option with a proven clinical benefit, or are intolerant to these therapies

4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 for Part A and 0-1 for Parts B, C and D

5. Hepatic function and adequate renal function, as per protocol standard

6. Adequate bone marrow function as per protocol standard

Exclusion Criteria

1. Unable or not willing to provide tumour tissue sample (from archival tissue or de-novo biopsy) unless if there is a significant risk for the patient to undergo biopsy

2. Has received investigational or anti-cancer therapy within 4 weeks (28 days) prior to starting study drug

3. Is receiving any concomitant anti-cancer therapy

4. Known severe hypersensitivity to E coli-derived products or filgrastim or peg-filgrastim and have significant allergies to such biological products

5. Has clinically active brain metastases

6. Has received prior radiation therapy

7. Has received prophylactic administration of haematopoietic colony stimulating factors within 4 weeks (28 days) prior to starting study drug

8. Patients concurrently using any strong P-glycoprotein (P-gp) inducers/inhibitors or strong cytochrome P3A (CYP3A) inhibitors within 14 days prior to the first dose of study drug or patients that use restricted or prohibited medications listed in the concomitant and other treatments section of the protocol

9. Pregnancy or breast feeding

10. For patients receiving pembrolizumab:

1. Has an active autoimmune disease that has required systemic treatment in the past 2 years

2. Patients who, according to the currently approved Keytruda (pembrolizumab) US package insert (USPI)/summary of product characteristics, had an immune-related adverse event (irAE) for which permanent discontinuation is mandated (any Grade 4 event and Grade 3 events of pneumonitis, hepatitis, and nephritis). Also, patients without formal contraindication due to previous irAE with any immune checkpoint inhibitor (approved or investigational) are not eligible if the AE has not resolved to grade 1 or better and/or still requires steroids (>10 mg of prednisone equivalent per day) for ongoing management.

3. Patients with a history of pneumonitis/interstitial lung disease, patients who received live vaccines within 30 days of enrolment, and patients who discontinued prior immune checkpoint inhibitors due to Grade 2 myocarditis are excluded from enrolment into pembrolizumab-containing cohorts

11. Has had a major surgical procedure within 4 weeks (28 days) from starting the study drug

12. Patients with active or chronic corneal disorders, with other active ocular conditions requiring ongoing therapy or with any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy

13. Active infection including HIV, Hepatitis B or Hepatitis C

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Parexel

INDUSTRY

Sponsor Role: collaborator

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Venkateshan Srirangam Prativadibhayankara, MD

Role: STUDY_DIRECTOR

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Locations

University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center

Aurora, Colorado, United States

Site Status: RECRUITING

UT MD Anderson Cancer Center

Houston, Texas, United States

Site Status: RECRUITING

National University Hospital - Medical Oncology

Singapore, South West, Singapore

Site Status: RECRUITING

National Cancer Centre Singapore

Singapore, South West, Singapore

Site Status: RECRUITING

Taipei Veterans General Hospital

Taipei, Taipei, Taiwan

Site Status: NOT_YET_RECRUITING

Countries

United States; Singapore; Taiwan

Central Contacts

Venkateshan Srirangam Prativadibhayankara, MD

Role: CONTACT

Venkateshan_Srirangam@eddc.sg

+65 6407 4213

Veronica Diermayr

Role: CONTACT

Veronica_Diermayr@eddc.sg

+65 6407 0706

Other Identifiers

EBC-129-01

Identifier Type: -

Identifier Source: org_study_id